Microbial Colonization in Lung Cancer Patients

Status Recruiting

Clinical Trial Summary

Primary Aim: -To determine the prevalence and pattern of bronchial colonization in patients presenting with lung cancer at the time of diagnosis Secondary Aim: -To assess the potential demographic, clinical, radiological and histological predictors of colonization in patients with lung cancer

Clinical Trial Description

Lung cancer is the world's most common neoplasm and its incidence is rising. Lung cancer has the highest mortality rates of all cancers. Pulmonary infections, especially pneumonia, frequently complicate the course of lung cancer and are often the ultimate cause of death. It has been suggested that bronchial colonization plays a key role in the establishment of pulmonary infections in patients with lung cancer, and thus clearly influences the therapeutic management and probably the prognosis of cancer. In such patients, colonization may arise following local bronchial impairment, e.g. stenosis or impaired mucociliary clearance, or be caused by more general abnormalities, including immunosuppression, malnutrition, smoking, chronic obstructive pulmonary disease (COPD) and chemotherapy. Studies indicate that bronchial colonization can be demonstrated in 48.1% of patients with lung cancer and may be caused by potential pathogenic microorganisms (PPMs), mainly Haemophilus influenzae, Streptococcus pneumoniae and Staphylococcus aureus. Other potential microbial agents, such as mycobacteria and fungi, have not been investigated systematically However, there is a wide variation in the microbial profile reported from the previous studies; some of which reporting predominance of Gram-positive organisms- streptococcus pneumoniae in particular, while more recent studies reported predominance of Gram-negative organisms, which may indicate a shift in the spectrum of organism colonizing bronchial tree of lung cancer patients in parallel to the increased trends of antibiotic exposures, something this study will re-examine. Moreover, given the paucity of literature highlighting the potential predictors of colonization in such patients, overlooking data on radiological findings in lung cancer patients and underreporting the impact of comorbidities, this study aims to further explore a wider array of potential demographic, clinical, radiological and histological determinants. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05748795
Study type	Observational [Patient Registry]
Source	Assiut University
Contact	Tasneem H Younes, resident
Phone	01069306183
Email	tassnem747@gmail.com
Status	Recruiting
Phase
Start date	February 1, 2023
Completion date	February 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05414994` - Assessment of the Ocular Microbiome in Health and Disease
Completed	`NCT04769882` - Er:YAG Laser Effects on Microbial Population in Conservative Dentistry	N/A
Completed	`NCT04766528` - Effect of Diet on the Microbiota / Endoccanabinoidome Axis in Response to Physical Activity	N/A
Completed	`NCT03720314` - Microbiota Profiling in IBS
Completed	`NCT04122612` - Shaping Microbiome in the First 1,000 Days of Life
Not yet recruiting	`NCT05405634` - Microbiota in Chronic Anal Fissure and Its Association With Prognosis
Not yet recruiting	`NCT04895774` - Ex Vivo Study of the Mechanism of Action of Active Ingredients on the Intestinal Microbiota
Recruiting	`NCT05992688` - The Sweet Kids Study (Stevia on Weight and Energy Effect Over Time)	N/A
Recruiting	`NCT05502380` - Broad-spectrum Antibiotic Prophylaxis in Tumor and Infected Orthopedic Surgery	Phase 3
Completed	`NCT05175833` - Oral Probiotics and Secondary Bacterial Pneumonia in Severe COVID-19	Phase 2
Recruiting	`NCT04836910` - Microbiome and Polycystic Ovaries
Recruiting	`NCT05603650` - Effects of Mouthrinses on the Microbiome of the Oral Cavity and GI Tract	N/A
Completed	`NCT04991818` - MSC - OneBiome UX Pilot Study	N/A
Completed	`NCT05575050` - Impact of Teeth Brushing in Ventilated COVID-19 Patients.	N/A
Completed	`NCT04374955` - The Effect of Probiotic Added to Maternal Diet on Infantile Colic and Intestinal Microbiota Content	N/A
Recruiting	`NCT04140747` - Transfer of Strictly Anaerobe Microbes From Mother to Child
Recruiting	`NCT04111471` - The Use of A Prebiotic to Promote a Healthy Gut Microbiome in Pediatric Stem Cell Transplant Recipients	N/A
Suspended	`NCT03220282` - The Milk, Growth and Microbiota Study	N/A
Completed	`NCT03422562` - Probiotics and Intestinal Microbiome in Preterm Infants	Phase 3
Recruiting	`NCT05695196` - Feasibility and Safety Study of Parent-to-Child Nasal Microbiota Transplant	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.